Articles: coronavirus.
-
Randomized Controlled Trial
The efficacy of combined therapy of qingfeiPaidu capsule and lianhuaqingwen capsule nursing interventions for hospitalized patients with COVID-19: A retrospective study of medical records.
Coronavirus disease-19 (COVID-19) caused a global pandemic burden, affecting hundreds of thousands of individuals, having life-threatening outcomes. Traditional Chinese Medicine plays a crucial role in the treatment of patients with COVID-19. The purpose of this study was to investigate the efficacy of combined therapy of qingfeiPaidu (QFPD) capsule and lianhuaqingwen (LHQW) capsule nursing interventions in the treatment of patients with COVID-19. ⋯ All patients met the discharge criteria after 30-day treatment in 3 groups. Combined therapy of QFPD and LHQW demonstrated significant anti-inflammatory effects compared with those of only QFPD or LHQW in patients with mild and moderate COVID-19. The combined therapies may alleviate clinical symptoms of COVID-19 patients by improving inflammation and immune function.
-
Since the outbreak of the Corona pandemic in December 2019, many people affected, especially medical care laborers, who deal with the treated cases. Coronavirus disease 2019 not only affects the body parts, but also extends to the psychological symptoms. The purpose of this research is to explore the impact of the pandemic on the mental prosperity of the laborers. ⋯ Attendants, paramedics, and those working in the detachment unit showed a critical sleeping disorder. The results and indicators have proven that there is a relationship between the infection with the Corona pandemic and occurrence of disorders in psychological behavior. Therefore, the psychological rehabilitation sessions must be conducted for those infected and those in contact with the Corona cases to relieve the burden of that patients to raise their psychological conditions and support the immune system such that resist against the infection.
-
Observational Study
Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021.
This observation study examines coronavirus disease 2019 (COVID-19) data from outbreak and other sites in China and worldwide in order to examine the epidemiological pattern of COVID-19 before the acquisition of immunity through widespread vaccination and infection. COVID-19-related morbidity and mortality data for January 2020 to February 2021 were obtained from the Chinese Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, and the World Health Organization. The number of cases was logarithmically transformed for comparison of the rate of increase or decrease with time across areas. ⋯ After the early stage, similar increase in the incidence rate with time was observed globally, although the total number of cases differed between regions. The outbreak severe acute respiratory syndrome coronavirus 2 strain in Wuhan had low epidemic intensity and high virulence, but the epidemiological characteristics of severe acute respiratory syndrome coronavirus 2 may not be associated with race, geography, or economic status. Importantly, more effective prevention and control measures and vaccines should be applied for controlling the variants.
-
Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking. ⋯ During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age.
-
Tohoku J. Exp. Med. · Aug 2022
Case ReportsCOVID-19 in a Hairy Cell Leukemia Patient: A Rare Case Report.
The detailed clinical course of coronavirus disease 2019 (COVID-19) in patients with hairy cell leukemia (HCL) is rarely reported. We report the first case of HCL diagnosed with prolonged pancytopenia after COVID-19 infection in Japan. We describe the case of a 56-year-old man who was diagnosed with COVID-19. ⋯ Further, the condition of all previously reported patients with COVID-19 associated with HCL was severe enough to require mechanical ventilation. This is the first case in which the disease was not severe. The interleukin-6 (IL-6) level was lower in this case than in previous cases, suggesting that racial differences in IL-6 production may have contributed to COVID-19 severity.